Belay Diagnostics, an innovative CLIA/CAP accredited laboratory focused on the development and commercialization of molecular diagnostics targeting central nervous system (CNS) cancers, announced the ...

Lifespan Vision Ventures, an investment firm focused on therapeutics that improve human healthspan, today announced that it ...

Sift Biosciences, a UC Berkeley spinout developing a next-generation peptide immunotherapy platform that integrates AI, metagenomics, and high-throughput immune profiling, today announced the closing ...

NanoAvionics to offer satellite operators the option of real-time optical connectivity and on-orbit compute services through Kepler’s network ...

"The FDA approval of Optune Pax marks the first new treatment in decades for people living with locally advanced pancreatic ...

Baystreet.ca News Commentary – The FDA issued more than 50 oncology approvals in 2025, with most of those concentrated in immunotherapy and targeted therapy, and January 2026 ...

In January 2026 alone, the FDA granted orphan drug designations for agents targeting gastrointestinal cancers and myelofibrosis, as well as breakthrough therapy designations across several rare ...

We are responding to the challenge of the polycrisis by evolving. Our goal is to make use of the very best solutions ...

Jacob Lalezari of CytoDyn shares insights about CCR5-targeting therapy for cancer, including triple negative breast cancer and colorectal cancer.

Tiny earth observation satellites in 2026 track hurricanes, crops, and ships with CubeSat weather monitoring, small satellite ...

A strategic cooperation agreement linking the Cypriot and Greek space technology ecosystems was signed on Thursday in Nicosia ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...